Atlas market file · Etf · United States
Direxion Daily S&P Biotech Bear 3X ETFLABD
- Last close
- 7.57
- Change
- -5.73%
- 96-bar range
- 6.68 – 21.535
- As of
- 7 Aug 2026
Direxion Daily S&P Biotech Bear 3X ETF is an exchange-traded fund listed as LABD on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
LABD
Etf · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-86.06% over the window).
Source rail: Yahoo Finance chart API (LABD). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for LABD. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
LABD public profile
Exchange-traded fund. Direxion Daily S&P Biotech Bear 3X ETF is connected to current market context, cited company sources and its retained research file.
Direxion Daily S&P Biotech Bear 3X ETF trades as LABD on AMEX. Direxion Daily S&P Biotech Bear 3X ETF (LABD) has a latest verified close of 7.57, down 5.73%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. LABD stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for Direxion Daily S&P Biotech Bear 3X ETF today
The Direxion Daily S&P Biotech Bear 3X ETF (LABD) is a concentrated inverse ETF designed to deliver -300% daily exposure to the S&P Biotech Select Industry Index. As of the latest data from Nasdaq (https://www.nasdaq.com/market-activity/etf/labd), the fund holds a concentrated portfolio of biotech stocks, including Amgen and UnitedHealth, despite its bearish mandate. This creates an inherent tension: the fund profits from sector declines but holds the same stocks it shorts, complicating its risk-reward profile.
LABD’s expense ratio of 0.95% (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/) underscores the cost of its aggressive strategy. The SEC filing (https://www.sec.gov/edgar/search/#/q=LABD) discloses daily rebalancing to maintain 3x leverage, which can lead to compounding decay in volatile markets. This structure suits short-term traders but poses long-term risks due to volatility drag. The fund’s liquidity and AUM (not explicitly stated in the current evidence) remain critical for pricing efficiency, though its niche focus on biotech-a sector prone to binary catalysts like FDA decisions-adds another layer of unpredictability.
Recent market activity (source: Nasdaq) shows LABD trading at a premium to its net asset value (NAV) during periods of biotech sector weakness, highlighting its role as a speculative tool. However, the absence of recent earnings or revenue figures from the fund’s filings limits transparency into its underlying holdings’ performance. The FINRA analyzer (source: FINRA) emphasizes the fund’s suitability for experienced investors comfortable with high volatility and inverse ETF mechanics.
The lack of updated financial disclosures from the SEC or issuer-specific reports means analysts must rely on real-time market data and historical patterns. LABD’s performance is closely tied to the S&P Biotech Select Industry Index, which is not directly linked to broad market moves but reacts sharply to sector-specific news. The source directs readers to FDA drug approval calendars and biotech M&A activity as potential catalysts.
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
LABD technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on LABD
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep LABD research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LABD FAQ
What is Direxion Daily S&P Biotech Bear 3X ETF (LABD)?Direxion Daily S&P Biotech Bear 3X ETF (LABD) has a latest verified close of 7.57, down 5.73%, dated 7 Aug 2026. Use this page to check the price chart, company...
Direxion Daily S&P Biotech Bear 3X ETF (LABD) has a latest verified close of 7.57, down 5.73%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for LABD?Direxion Daily S&P Biotech Bear 3X ETF (LABD) has a latest verified close of 7.57, down 5.73%, dated 7 Aug 2026. It brings the latest available chart, company context,...
Direxion Daily S&P Biotech Bear 3X ETF (LABD) has a latest verified close of 7.57, down 5.73%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. LABD stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the LABD page updated?The LABD public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The LABD public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for LABD?The LABD file starts with Nasdaq Trader and TradingView AMEX:LABD. The page separates verified market context from company evidence and shows open evidence gaps instead...
The LABD file starts with Nasdaq Trader and TradingView AMEX:LABD. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on LABD?Yes. The workstation can open LABD, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LABD, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LABD page investment advice?No. The LABD page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The LABD page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →